Sequence variants at 22q13 are associated with prostate cancer risk

Jielin Sun, Siqun Lilly Zheng, Fredrik Wiklund, Sarah D. Isaacs, Ge Li, Kathleen E. Wiley, Seong Tae Kim, Yi Zhu, Zheng Zhang, Fang Chi Hsu, Aubrey R. Turner, Pär Stattin, Wennuan Liu, Woo Kim Jin, David Duggan, John Carpten, William B Isaacs, Henrik Grönberg, Jianfeng Xu, Bao Li Chang

Research output: Contribution to journalArticle

Abstract

To search for genetic variants that are associated with prostate cancer risk in the genome, we combined the data from our genome-wide association study (GWAS) in a population-based case-control study in Sweden with publicly available GWAS data from the Cancer Genetic Markers of Susceptibility (CGEMS) study. We limited the cases to those with aggressive disease in an attempt to identify risk variants that are associated with this most clinically relevant form of the disease. Among the most likely candidate single nucleotide polymorphisms (SNP) identified from the two GWAS, we sequentially confirmed one SNP at 22q13 in two independent study populations: the remaining subjects in Cancer of the Prostate in Sweden and a hospital-based case-control study at Johns Hopkins Hospital. Association of aggressive prostate cancer with the SNP at 22q13 was also observed in the publicly available data of four additional study populations from the second stage of the CGEMS study. In all seven study populations examined, the frequency of allele "C" of rs9623117 at 22q13 was consistently higher in aggressive cases than in controls. The combined allelic test was highly significant, with P = 5.0 × 10-7. The odds ratio (OR) of allele C for aggressive prostate cancer was estimated to be 1.18 [95% confidence interval (95% CI), 1.11-1.26]. However, the SNP was also associated with nonaggressive prostate cancer, with an estimated OR of 1.11 (95% CI, 1.04-1.19; P = 0.004). The risk-associated variants are located within the genomic region of TNRC6B, a gene involved in miRNA-mediated mRNA degradation. Additional studies are warranted to further confirm the association.

Original languageEnglish (US)
Pages (from-to)10-15
Number of pages6
JournalCancer Research
Volume69
Issue number1
DOIs
StatePublished - Jan 1 2009

Fingerprint

Prostatic Neoplasms
Single Nucleotide Polymorphism
Genome-Wide Association Study
Genetic Predisposition to Disease
Genetic Markers
Sweden
Population
Case-Control Studies
Odds Ratio
Confidence Intervals
Second Primary Neoplasms
RNA Stability
MicroRNAs
Gene Frequency
Alleles
Genome
Genes
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Sun, J., Zheng, S. L., Wiklund, F., Isaacs, S. D., Li, G., Wiley, K. E., ... Chang, B. L. (2009). Sequence variants at 22q13 are associated with prostate cancer risk. Cancer Research, 69(1), 10-15. https://doi.org/10.1158/0008-5472.CAN-08-3464

Sequence variants at 22q13 are associated with prostate cancer risk. / Sun, Jielin; Zheng, Siqun Lilly; Wiklund, Fredrik; Isaacs, Sarah D.; Li, Ge; Wiley, Kathleen E.; Kim, Seong Tae; Zhu, Yi; Zhang, Zheng; Hsu, Fang Chi; Turner, Aubrey R.; Stattin, Pär; Liu, Wennuan; Jin, Woo Kim; Duggan, David; Carpten, John; Isaacs, William B; Grönberg, Henrik; Xu, Jianfeng; Chang, Bao Li.

In: Cancer Research, Vol. 69, No. 1, 01.01.2009, p. 10-15.

Research output: Contribution to journalArticle

Sun, J, Zheng, SL, Wiklund, F, Isaacs, SD, Li, G, Wiley, KE, Kim, ST, Zhu, Y, Zhang, Z, Hsu, FC, Turner, AR, Stattin, P, Liu, W, Jin, WK, Duggan, D, Carpten, J, Isaacs, WB, Grönberg, H, Xu, J & Chang, BL 2009, 'Sequence variants at 22q13 are associated with prostate cancer risk', Cancer Research, vol. 69, no. 1, pp. 10-15. https://doi.org/10.1158/0008-5472.CAN-08-3464
Sun J, Zheng SL, Wiklund F, Isaacs SD, Li G, Wiley KE et al. Sequence variants at 22q13 are associated with prostate cancer risk. Cancer Research. 2009 Jan 1;69(1):10-15. https://doi.org/10.1158/0008-5472.CAN-08-3464
Sun, Jielin ; Zheng, Siqun Lilly ; Wiklund, Fredrik ; Isaacs, Sarah D. ; Li, Ge ; Wiley, Kathleen E. ; Kim, Seong Tae ; Zhu, Yi ; Zhang, Zheng ; Hsu, Fang Chi ; Turner, Aubrey R. ; Stattin, Pär ; Liu, Wennuan ; Jin, Woo Kim ; Duggan, David ; Carpten, John ; Isaacs, William B ; Grönberg, Henrik ; Xu, Jianfeng ; Chang, Bao Li. / Sequence variants at 22q13 are associated with prostate cancer risk. In: Cancer Research. 2009 ; Vol. 69, No. 1. pp. 10-15.
@article{4cd2b1d0c5d34c05a78a03e8cb90558c,
title = "Sequence variants at 22q13 are associated with prostate cancer risk",
abstract = "To search for genetic variants that are associated with prostate cancer risk in the genome, we combined the data from our genome-wide association study (GWAS) in a population-based case-control study in Sweden with publicly available GWAS data from the Cancer Genetic Markers of Susceptibility (CGEMS) study. We limited the cases to those with aggressive disease in an attempt to identify risk variants that are associated with this most clinically relevant form of the disease. Among the most likely candidate single nucleotide polymorphisms (SNP) identified from the two GWAS, we sequentially confirmed one SNP at 22q13 in two independent study populations: the remaining subjects in Cancer of the Prostate in Sweden and a hospital-based case-control study at Johns Hopkins Hospital. Association of aggressive prostate cancer with the SNP at 22q13 was also observed in the publicly available data of four additional study populations from the second stage of the CGEMS study. In all seven study populations examined, the frequency of allele {"}C{"} of rs9623117 at 22q13 was consistently higher in aggressive cases than in controls. The combined allelic test was highly significant, with P = 5.0 × 10-7. The odds ratio (OR) of allele C for aggressive prostate cancer was estimated to be 1.18 [95{\%} confidence interval (95{\%} CI), 1.11-1.26]. However, the SNP was also associated with nonaggressive prostate cancer, with an estimated OR of 1.11 (95{\%} CI, 1.04-1.19; P = 0.004). The risk-associated variants are located within the genomic region of TNRC6B, a gene involved in miRNA-mediated mRNA degradation. Additional studies are warranted to further confirm the association.",
author = "Jielin Sun and Zheng, {Siqun Lilly} and Fredrik Wiklund and Isaacs, {Sarah D.} and Ge Li and Wiley, {Kathleen E.} and Kim, {Seong Tae} and Yi Zhu and Zheng Zhang and Hsu, {Fang Chi} and Turner, {Aubrey R.} and P{\"a}r Stattin and Wennuan Liu and Jin, {Woo Kim} and David Duggan and John Carpten and Isaacs, {William B} and Henrik Gr{\"o}nberg and Jianfeng Xu and Chang, {Bao Li}",
year = "2009",
month = "1",
day = "1",
doi = "10.1158/0008-5472.CAN-08-3464",
language = "English (US)",
volume = "69",
pages = "10--15",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "1",

}

TY - JOUR

T1 - Sequence variants at 22q13 are associated with prostate cancer risk

AU - Sun, Jielin

AU - Zheng, Siqun Lilly

AU - Wiklund, Fredrik

AU - Isaacs, Sarah D.

AU - Li, Ge

AU - Wiley, Kathleen E.

AU - Kim, Seong Tae

AU - Zhu, Yi

AU - Zhang, Zheng

AU - Hsu, Fang Chi

AU - Turner, Aubrey R.

AU - Stattin, Pär

AU - Liu, Wennuan

AU - Jin, Woo Kim

AU - Duggan, David

AU - Carpten, John

AU - Isaacs, William B

AU - Grönberg, Henrik

AU - Xu, Jianfeng

AU - Chang, Bao Li

PY - 2009/1/1

Y1 - 2009/1/1

N2 - To search for genetic variants that are associated with prostate cancer risk in the genome, we combined the data from our genome-wide association study (GWAS) in a population-based case-control study in Sweden with publicly available GWAS data from the Cancer Genetic Markers of Susceptibility (CGEMS) study. We limited the cases to those with aggressive disease in an attempt to identify risk variants that are associated with this most clinically relevant form of the disease. Among the most likely candidate single nucleotide polymorphisms (SNP) identified from the two GWAS, we sequentially confirmed one SNP at 22q13 in two independent study populations: the remaining subjects in Cancer of the Prostate in Sweden and a hospital-based case-control study at Johns Hopkins Hospital. Association of aggressive prostate cancer with the SNP at 22q13 was also observed in the publicly available data of four additional study populations from the second stage of the CGEMS study. In all seven study populations examined, the frequency of allele "C" of rs9623117 at 22q13 was consistently higher in aggressive cases than in controls. The combined allelic test was highly significant, with P = 5.0 × 10-7. The odds ratio (OR) of allele C for aggressive prostate cancer was estimated to be 1.18 [95% confidence interval (95% CI), 1.11-1.26]. However, the SNP was also associated with nonaggressive prostate cancer, with an estimated OR of 1.11 (95% CI, 1.04-1.19; P = 0.004). The risk-associated variants are located within the genomic region of TNRC6B, a gene involved in miRNA-mediated mRNA degradation. Additional studies are warranted to further confirm the association.

AB - To search for genetic variants that are associated with prostate cancer risk in the genome, we combined the data from our genome-wide association study (GWAS) in a population-based case-control study in Sweden with publicly available GWAS data from the Cancer Genetic Markers of Susceptibility (CGEMS) study. We limited the cases to those with aggressive disease in an attempt to identify risk variants that are associated with this most clinically relevant form of the disease. Among the most likely candidate single nucleotide polymorphisms (SNP) identified from the two GWAS, we sequentially confirmed one SNP at 22q13 in two independent study populations: the remaining subjects in Cancer of the Prostate in Sweden and a hospital-based case-control study at Johns Hopkins Hospital. Association of aggressive prostate cancer with the SNP at 22q13 was also observed in the publicly available data of four additional study populations from the second stage of the CGEMS study. In all seven study populations examined, the frequency of allele "C" of rs9623117 at 22q13 was consistently higher in aggressive cases than in controls. The combined allelic test was highly significant, with P = 5.0 × 10-7. The odds ratio (OR) of allele C for aggressive prostate cancer was estimated to be 1.18 [95% confidence interval (95% CI), 1.11-1.26]. However, the SNP was also associated with nonaggressive prostate cancer, with an estimated OR of 1.11 (95% CI, 1.04-1.19; P = 0.004). The risk-associated variants are located within the genomic region of TNRC6B, a gene involved in miRNA-mediated mRNA degradation. Additional studies are warranted to further confirm the association.

UR - http://www.scopus.com/inward/record.url?scp=58249121582&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58249121582&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-08-3464

DO - 10.1158/0008-5472.CAN-08-3464

M3 - Article

C2 - 19117981

AN - SCOPUS:58249121582

VL - 69

SP - 10

EP - 15

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 1

ER -